Influenza

Importance of properly diagnosing COVID-19 vs influenza to offer therapeutics.

Potential changes within office visits for COVID-19 and influenza.

Differentiating between COVID-19 and influenza.

Challenges in messaging as the understanding of COVID-19 evolves.

Several reasons patients are reluctant to getting the flu vaccine.

Promise of a dual COVID-19/influenza vaccine in development.

Slight variation in the flu vaccine from last season based on limited data.

A discussion on the lifting of COVID-19 restrictions and the potential impact on the upcoming flu season.

Panel speculates on the upcoming flu season for 2021-2022.

Multiple factors contributing to a lower-than-average flu season in 2020-2021 are discussed.

While the COVID-19 pandemic has helped advance respiratory diagnostics and surveillance, there are still many gaps that remain across the spectrum of healthcare.

A look at the COVID-19 driven factors for this upcoming influenza season, from reopening classrooms to reduced mutation chances.

A conversation with William Schaffner, MD.

The study was the largest of its kind looking at the flu shot and COVID-19.

FluGen announced its vaccine candidate, Bris2007 M2SR, induced neutralizing antibodies against infection and illness following a challenge with an antigenically distinct virus.

A clinical decision support (CDS) strategy including a default influenza vaccine order for eligible patients, a nursing script using a presumptive strategy, and education for clinicians, was associated with significant improvement in vaccination rates among hospitalized children, a new study showed.

Last influenza season was notably quiet during peaking COVID-19 cases. Experts explain what may influence risk of dueling epidemics this year.

A group of personnel at a veterans administration medical center (VAMC)) did a drive-thru to help bolster vaccination amongst coworkers.

The company’s mRNA-1010 is a seasonal influenza vaccine candidate that is targeting A H1N1, H3N2, influenza B Yamagata, and Victoria lineages.

Seqirus is seeking reactogenicity and immunogenicity outcomes between its influenza vaccines and available mRNA vaccines for COVID-19.

Plus: how could the COVID-19 testing market boom improve public flu awareness?

COVID-19 response restrained flu outbreaks last year. An expert explains his concern that won't be enough this winter.

An interview with a study author on new Novavax-Seqirus co-administration trial data, and the future concerns of circulating COIVD-19 and influenza.

The device may help clinicians differentiate between past infections and co-infections during the upcoming flu season.

In a population-based cohort study with a mean follow-up of 3.6 years, childhood outcomes showed no statistically significant associations with any adverse health conditions.

A discussion with the CDC’s Flu Czar, Lynnette Brammer, surrounding the upcoming flu season and what we can expect due to the COVID-19 pandemic.

The government agency will be assessing the safety and immunogenicity of an investigational nanoparticle influenza vaccine.

A concerted effort to increase flu vaccination during the COVID-19 pandemic resulted in more protection among a high-risk population, as well as educational opportunities for pharmacy students.

NanoFlu/NVX-CoV2373 elicited functional influenza and COVID-19 antibodies in ferrets 2 weeks after vaccination.

The frontline assay from Abbott will help differentiate among 4 respiratory viruses in real-time.